Could hepatitis c kidneys be the answer to organ shortage?
NCT ID NCT04075916
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This study tested whether kidneys from donors with hepatitis C can be safely transplanted into patients without the virus. After transplant, recipients took a 12-week course of the antiviral drug Epclusa to cure any infection. The goal was to see if this approach could help more people get kidney transplants faster, while keeping them healthy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Jackson Memorial Hospital/University of Miami
Miami, Florida, 33136, United States
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
New York Presbyterian Hospital/Columbia University
New York, New York, 10032, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Florida
Gainesville, Florida, 32608, United States
-
Vanderbilt University
Nashville, Tennessee, 37235, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sofosbuvir/velpatasvir (Epclusa)
What this could lead to
If successful, this could expand the donor kidney pool by safely using organs from hepatitis C-infected donors, reducing wait times for transplant candidates.
What could go wrong
This is a mid-stage trial with 201 participants; results may not apply to all patients. There is a risk of hepatitis C transmission or other complications despite antiviral treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.